Core Insights - Kintor Pharmaceutical (02171.HK) announced clinical data for its universal BCMA CAR-T product CT0596 and universal CD19/CD20 CAR-T product CT1190B, both showing promising safety and efficacy signals for treating relapsed/refractory multiple myeloma (R/R MM) and non-Hodgkin lymphoma (R/R NHL) respectively [1][2] Group 1: Product Development - CT0596 is a universal CAR-T cell therapy targeting BCMA, currently undergoing investigator-initiated clinical trials for R/R MM and plasma cell leukemia (PCL), with plans to submit an IND application in the second half of 2025 [1] - CT1190B targets CD19/CD20 and is involved in clinical trials for treating relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL) and severe refractory systemic lupus erythematosus (SLE) or refractory/progressive systemic sclerosis (SSc) [2] Group 2: Company Overview - Kintor Pharmaceutical is a biopharmaceutical company focused on developing innovative CAR-T cell therapies to address unmet clinical needs, including hematologic malignancies, solid tumors, and autoimmune diseases [2] - The company has established end-to-end capabilities in CAR-T cell research and development, from target discovery to commercial-scale production, positioning itself as a leading global player in CAR-T therapy [2] - Kintor currently has 10 CAR-T pipeline products, including 4 autologous CAR-T and 6 universal CAR-T, all of which are self-developed with global rights [2]

Core Viewpoint - Kintor Pharmaceutical Co., Ltd. (02171.HK) experienced a significant intraday increase of over 8%, with a current rise of 6.31%, trading at HKD 17.52, and a transaction volume of HKD 51.9354 million [2] Company Summary - Kintor Pharmaceutical's stock price showed a notable increase during trading, indicating positive market sentiment towards the company [2] - The trading volume reached HKD 51.9354 million, reflecting active investor interest [2]

Core Viewpoint - The stock of Kintor Pharmaceutical (02171) has seen a significant increase, rising over 8% during trading, with a current price of HKD 17.52 and a trading volume of HKD 51.9354 million. This surge is linked to the ongoing negotiations for the 2025 National Medical Insurance pricing, which may positively impact CAR-T therapies, including Kintor's Zewokaiolun injection [1]. Group 1 - The negotiations for the 2025 National Medical Insurance are currently in their fourth day, with representatives from HeYuan Bio expressing that discussions have been smooth, although final results will depend on the National Healthcare Security Administration's announcement [1]. - There are currently seven CAR-T products approved in China, all priced over one million yuan, with five undergoing review through the commercial insurance directory, including Kintor's Zewokaiolun injection [1]. - Inclusion of CAR-T therapies in the commercial insurance directory is expected to enhance patient accessibility, reduce financial burdens, alleviate pricing pressure on pharmaceutical companies, expand market share, and ensure reasonable returns for high-value innovative therapies [1].

Core Insights - The Chinese innovative pharmaceutical industry is experiencing a "triple resonance" recovery, driven by continuous optimization of the industrial chain and active policy and capital injection [1][12] - The third-quarter reports from leading innovative pharmaceutical companies reflect this trend and serve as an important window for observing industry dynamics and future development prospects [1] Company Performance - Heng Rui Medicine reported a revenue of 23.188 billion yuan for the first three quarters of 2025, a year-on-year increase of 14.85%, and a net profit of 5.751 billion yuan, up 24.50% [1] - The company maintained high R&D investment, with R&D expenses reaching 4.945 billion yuan in the first three quarters, totaling over 50 billion yuan cumulatively [1] - East China Pharmaceutical achieved a revenue of 32.664 billion yuan, a 3.77% increase, and a net profit of 2.748 billion yuan, up 7.24% [2] Innovation and R&D Progress - Heng Rui has received approval for 24 first-class innovative drugs and 5 second-class new drugs in China, with 13 new drug applications accepted by the National Medical Products Administration in the first three quarters [3][4] - East China Pharmaceutical has achieved breakthroughs in first-in-class innovative drugs and is advancing over 90 innovative drug pipeline projects [4] - The new round of "National Major Special Projects for Innovative Drug Development" aims to enhance the country's drug research capabilities and transition from imitation to innovation [6] Market Dynamics and Challenges - The domestic innovative drug market is at a critical stage of "quantity increase and quality change," with increasing pressure on payment systems and a shift in market demands from "availability" to "quality" [7][11] - The concentration of popular drug targets in China is high, with the top 20 targets accounting for 41%, compared to 28% in the U.S., indicating a need for more diverse innovation [5] Business Development and International Collaboration - In 2025, business development (BD) transactions in the innovative drug sector have become a focal point, with Heng Rui entering significant collaborations with GSK and other companies [8][9] - The total value of BD transactions in the first half of the year reached $63.55 billion, surpassing the total for 2024, indicating growing international recognition of domestic R&D capabilities [9] Capital Market Trends - The Hong Kong stock market has seen a resurgence in biotech financing, with 59 companies listed in the first eight months of 2025, raising a net amount of 134.466 billion HKD [13] - Despite the recovery, the primary market for healthcare financing has shown a decline, with a 14% decrease in the number of financing transactions compared to the previous year [14]

Core Insights - The report emphasizes the significant role of phosphoramidite monomers in the small nucleic acid industry chain, highlighting their impact on the development of small nucleic acid drugs, which are considered promising candidates for treating various diseases due to their unique molecular structures and therapeutic mechanisms [1][6][10] - The report predicts robust growth in the demand for phosphoramidite monomers, with multinational pharmaceutical companies likely to benefit from this trend, as the global nucleotide market is projected to reach USD 730 million in 2023, with China being the largest production market [10][11] Section Summaries Phosphoramidite Monomer's Role - Phosphoramidite monomers are crucial raw materials for synthesizing small nucleic acid drugs, enhancing their stability and biological activity, and driving innovation in drug development [6][9] - The solid-phase phosphoramidite method is the mainstream technique for synthesizing oligonucleotides, which are a major cost component in nucleic acid drug production [9] Market Dynamics - The report notes that 90% of global nucleotides are used for nucleic acid drug production, with only about 10% allocated to health foods and agriculture [10] - The small nucleic acid drug market is primarily dependent on major multinational pharmaceutical companies, indicating potential benefits for companies within their supply chains [11] Investment Recommendations - The report suggests focusing on innovative drug companies such as Furuya Co., OncoOne, and others, as well as raw material suppliers like WuXi AppTec and others, indicating a diverse range of investment opportunities in the sector [10]

Core Insights - The Chinese innovative pharmaceutical industry is experiencing a "triple resonance" recovery driven by continuous optimization of the industrial chain and active policy and capital injection [1] - The third-quarter reports from leading innovative pharmaceutical companies reflect this trend and serve as an important window for observing industry dynamics and future development prospects [1] Company Performance - Heng Rui Medicine reported a revenue of 23.188 billion yuan for the first three quarters of 2025, a year-on-year increase of 14.85%, and a net profit of 5.751 billion yuan, up 24.50% [2] - The company maintained high R&D investment, with R&D expenses reaching 4.945 billion yuan in the first three quarters, totaling over 50 billion yuan cumulatively [2][3] - East China Pharmaceutical achieved a revenue of 32.664 billion yuan, a 3.77% increase year-on-year, and a net profit of 2.748 billion yuan, up 7.24% [2] Innovation and R&D - Heng Rui has received approval for 24 first-class innovative drugs and 5 second-class new drugs in China, with 13 new drug applications accepted by the National Medical Products Administration in the first three quarters [3][4] - East China Pharmaceutical has achieved breakthroughs in first-in-class innovative drugs and is advancing over 90 innovative drug pipeline projects [4] - The industry is witnessing a shift from "仿" (generic) to "创" (innovative) drug development, with a focus on building new drug creation capabilities [6][10] Market Dynamics - The domestic innovative drug market is at a critical stage of "quantity increase and quality change," with increasing pressure on payment systems and a shift in market demands from "existence" to "excellence" [7][10] - The number of international licensing collaborations between Chinese innovative drug companies and foreign companies has been increasing, with a total of 63.55 billion USD in business development transactions in the first half of 2025 [8] Future Outlook - The new round of major projects aims to achieve four transformations over ten years, focusing on upstream innovation chains and enhancing the capacity for new drug creation [6] - The Hong Kong stock market has become a major financing center for biotechnology, with 59 companies listed in the first eight months of 2025, raising a net amount of 134.466 billion HKD [12] - The establishment of a friendly market system for innovative drugs is crucial for sustainable development in the pharmaceutical industry [11]

Investment Rating - The report maintains an investment rating of "Outperform" with a rating of A [5] Core Insights - The report highlights the significant performance of domestic new drugs showcased at the ESMO 2025 conference, with several companies presenting excellent clinical data [3][21] - The report emphasizes the importance of academic conferences as key catalysts for the innovative drug sector, particularly mentioning ESMO, ASCO, and WCLC as critical events for Chinese pharmaceutical companies [20] Weekly New Drug Market Review - From October 20 to October 26, 2025, the top five gainers in the new drug sector were: - 欧康维视 (+8.87%) - 君圣泰 (+8.21%) - 诺思兰德 (+7.07%) - 友芝友 (+4.42%) - 海创药业 (+3.73%) - The top five losers were: - 康宁杰瑞 (-17.72%) - 北海康成 (-14.42%) - 创胜集团 (-14.29%) - 宜明昂科 (-13.40%) - 来凯医药 (-12.40%) [16][17] Recommended Focus Stocks - The report suggests focusing on several stocks with potential catalysts, including: 1. Products with high overseas volume certainty after MNC certification: - PD-1 upgraded product: 三生制药 - GLP-1 asset: 联邦制药 - ADC assets: 科伦博泰, 百利天恒 2. Potential heavyweights for overseas MNC authorization: - PD-1 upgraded products: 康方生物, 信达生物 - Breakthroughs in autoimmune fields: 益方生物, 中国抗体 - Innovative target ADC: 复宏汉霖, 石药集团 3. Stocks likely to benefit from medical insurance negotiations and commercial insurance innovative drug directories: - Beneficiaries of medical insurance directory: 恒瑞医药, 康诺亚, 迈威生物, 智翔金泰, 海创药业 - Beneficiaries of commercial insurance innovative drug directory: 药明巨诺, 科济药业 [2][20] New Drug Approval and Acceptance - This week, four new drug or new indication applications were approved, and five new drug or new indication applications were accepted in the domestic market [9] - A total of 46 new drug clinical applications were approved, and 31 new drug clinical applications were accepted [10] Key Domestic Market Events - 信达生物 announced a global strategic partnership with Takeda to accelerate the development of new generation tumor immunotherapy and antibody-drug conjugate therapies [11] - 康宁杰瑞 and 石药集团 announced that their HER2 bispecific antibody-drug conjugate JSKN003 received breakthrough therapy designation from the CDE [11] - 和黄医药 presented clinical data for HMPL-A251 at the AACR-NCI-EORTC conference [11] Key Overseas Market Events - 罗氏 received FDA approval for Gazyva/Gazyvaro for the treatment of active lupus nephritis in adult patients [12] - Electra Therapeutics announced that its therapy ELA026 received breakthrough therapy designation from the FDA and PRIME qualification from the EMA [12] - 安斯泰来 announced that the FDA accepted its supplemental biologics license application for the antibody-drug conjugate Padcev in combination with Keytruda [12]

Core Viewpoint - Kintor Pharmaceutical Co., Ltd. (科济药业-B) has conducted share buybacks, indicating a strategy to enhance shareholder value amidst market fluctuations [2] Summary by Category Share Buyback Details - On October 23, Kintor Pharmaceutical repurchased 205,000 shares at prices ranging from HKD 16.470 to HKD 16.700, totaling HKD 3.3982 million [2] - The stock closed at HKD 16.550 on the same day, reflecting a decline of 1.78%, with total trading volume of HKD 26.4818 million [2] - Year-to-date, the company has completed two buybacks, acquiring a total of 455,000 shares for a cumulative amount of HKD 7.6679 million [2] Buyback Breakdown - Buyback details include: - Date: October 23, 2025; Shares repurchased: 205,000; Highest price: HKD 16.700; Lowest price: HKD 16.470; Total amount: HKD 3.3982 million [2] - Date: October 21, 2025; Shares repurchased: 250,000; Highest price: HKD 17.150; Lowest price: HKD 16.990; Total amount: HKD 4.2698 million [2]

Group 1 - The company Kintor Pharmaceutical Co., Ltd. (stock code 02171) announced a share buyback plan [1] - The company will spend HKD 3.3982 million to repurchase 205,000 shares [1]

Group 1 - The company, 科济药业-B (02171.HK), announced a share buyback on October 23, spending HKD 3.4 million to repurchase 205,000 shares [1]